Riskpilot← Back to searchSign inGet full accessTRIOLAB AS
ASActiveOrg 963538952Jogstadveien 21, 2007 KjellerWholesale of pharmaceutical and medical goods · NACE 4646Est. 199242 employeeswww.triolab.no
Revenue 2024
NOK 297,9M
+9% vs 2023
EBITDA margin
13.4%
-1% vs 2023
Equity ratio
25.7%
Financial strength
Net profit 2024
NOK 30M
-5% vs 2023
| Revenue | NOK 297,9M | +9% |
| EBITDA | NOK 40M | -1% |
| Net profit | NOK 30M | -5% |
| Total assets | NOK 113,2M | +1% |
| Equity | NOK 29M | +0% |
| Employees | 42 | — |
Legal name
TRIOLAB AS
Org number
963538952
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. januar 1992
Share capital
—
Employees
42 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Address
Jogstadveien 21, 2007 Kjeller
Phone
+4763835750
Email
info@bergmandiag.no
Website
www.triolab.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 296 679 | 535 689 | 332 158 | 273 348 | 297 868 |
| Staff expenses | −38 201 | −43 880 | −45 150 | −43 731 | −45 788 |
| EBITDA | 36 547 | 181 609 | 77 768 | 40 634 | 40 038 |
| Depreciation & amort. | −1 565 | −807 | −240 | −110 | −1 480 |
| EBIT | 34 982 | 180 802 | 77 528 | 40 524 | 38 558 |
| Net financials | −942 | −1 156 | −1 002 | 35 | −27 |
| Profit before tax | 34 040 | 179 646 | 76 526 | 40 559 | 38 531 |
| Tax | 7 490 | 39 522 | 16 852 | 8 923 | 8 482 |
| Net profit | 26 550 | 140 124 | 59 674 | 31 636 | 30 048 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 95 033 | 261 168 | 145 287 | 112 440 | 113 193 |
| Equity | 17 566 | 32 690 | 32 365 | 29 001 | 29 049 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 77 466 | 228 478 | 112 923 | 83 439 | 84 144 |
| Total debt | 77 466 | 228 478 | 112 923 | 83 439 | 84 144 |
EBITDA margin
13.4%
This company
15.8%
Market median
-15% vs market
20202024
Equity ratio
25.7%
This company
38.2%
Market median
-33% vs market
20202024
Return on equity
103.4%
This company
18.4%
Market median
+462% vs market
20202024
Net profit margin
10.1%
This company
8.1%
Market median
+25% vs market
20202024
Asset turnover
2.63×
This company
1.12×
Market median
+135% vs market
20202024
Debt / equity
2.90×
This company
0.62×
Market median
-368% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GL Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
TE Chief Executive Officer | Chief Executive Officer | 1999 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Former (1) | ||
| Chairman | 2018 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Addlife Ab | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TRIOLAB AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gøran Lysø-Jakobsen | Chief Executive Officer | 0 companies |
| Tove Elisabeth Hauge Nyhus | Chief Executive Officer | 0 companies |
| Göran Fredrik Brandt | Board of Directors | 0 companies |
| Rolf Ove Stefan Sandin | Chairman | 0 companies |
| Kai Tapani Rantanen | Chairman | 0 companies |